Highlights d Identification of 1-18, a highly broad and potent V H 1-46derived CD4bs antibody d 2.5-Å cryo-EM structure of 1-18-Env complex reveals interprotomer contacts d 1-18 overcomes VRC01-class resistance and restricts development of HIV-1 escape d Monotherapy with 1-18 maintains viral suppression in HIV-1 YU2 -infected humanized mice SUMMARY Broadly neutralizing antibodies (bNAbs) represent a promising approach to prevent and treat HIV-1 infection. However, viral escape through mutation of the HIV-1 envelope glycoprotein (Env) limits clinical applications. Here we describe 1-18, a new V H 1-46encoded CD4 binding site (CD4bs) bNAb with outstanding breadth (97%) and potency (GeoMean IC 50 = 0.048 mg/mL). Notably, 1-18 is not susceptible to typical CD4bs escape mutations and effectively overcomes HIV-1 resistance to other CD4bs bNAbs. Moreover, mutational antigenic profiling uncovered restricted pathways of HIV-1 escape. Of most promise for therapeutic use, even 1-18 alone fully suppressed viremia in HIV-1-infected humanized mice without selecting for resistant viral variants. A 2.5-Å cryo-EM structure of a 1-18-BG505 SOSIP.664 Env complex revealed that these characteristics are likely facilitated by a heavy-chain insertion and increased inter-protomer contacts. The ability of 1-18 to effectively restrict HIV-1 escape pathways provides a new option to successfully prevent and treat HIV-1 infection.
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In Brief
Broadly neutralizing antibodies targeting the HIV-1 envelope protein are a promising option for prevention and treatment of HIV-1 infection. However, development of viral resistance can limit clinical efficacy. Schommers et al. identify a highly broad and potent antibody that targets the CD4 binding site of HIV-1. Compared with other potent CD4 binding site antibodies, it restricts the development of viral escape and effectively suppresses HIV-1 in vivo. Overcoming VRC01-class escape
INTRODUCTION
Broadly neutralizing antibodies (bNAbs) targeting the HIV-1 envelope protein (Env) can prevent infection in animal models and are under investigation for passive immunization in clinical trials (Balazs et al., 2011; Gautam et al., 2016; Julg and Barouch, 2019; Moldt et al., 2012; Shingai et al., 2014) . Moreover, bNAbs have been demonstrated to suppress viremia and delay viral rebound after interruption of antiretroviral therapy (ART) in HIV-1-infected individuals ; Bar-On et al., 2018; Caskey et al., 2015 Caskey et al., , 2017 Lynch et al., 2015a; Mendoza et al., 2018; Scheid et al., 2016) . Although these results highlight the significant clinical potential of bNAbs, pre-existing or de novo HIV-1 resistance cause treatment failure and can strongly limit bNAb applications in humans ; Bar-On et al., 2018; Caskey et al., 2015 Caskey et al., , 2017 Lynch et al., 2015a; Mendoza et al., 2018; Scheid et al., 2016) . Strategies to prevent and overcome viral escape are therefore critical to effectively implement bNAb-mediated approaches for HIV-1 prevention and therapy (Caskey et al., 2019; Gruell and Klein, 2018) . In recent years, potent bNAbs have been isolated from HIV-1infected donors that target distinct vulnerable epitopes on the Env trimer. These epitopes include the CD4 binding site (CD4bs), the V1/V2 loop, the V3 loop glycan patch, the membrane-proximal external region (MPER), and the interface (legend continued on next page) between the gp120 and gp41 subunits (Gama and Koup, 2018; Sok and Burton, 2018; Walker and Burton, 2018) . Among these sites, the CD4bs is of particular interest because CD4 serves as the primary receptor for viral entry Maddon et al., 1986; Zhou et al., 2007) . Most potent CD4bs bNAbs are characterized by use of the immunoglobulin heavy-chain gene segment IGVH1-2*02, high levels of somatic hypermutation, a five-residue complementarity-determining region 3 of the light chain (CDRL3), and mimicry of the CD4-Env interaction (West et al., 2012; Zhou et al., 2010 Zhou et al., , 2013 Zhou et al., , 2015 . Named after the prototypical antibody, these antibodies are referred to as VRC01-class bNAbs . Additional members of this class include 3BNC117, NIH45-46, N49-P7, N6, and VRC07-523 (Huang et al., 2016a; Rudicell et al., 2014; Sajadi et al., 2018; Scheid et al., 2011) . Other bNAbs that mimic CD4 binding are derived from the V H 1-46 gene segment. However, compared with V H 1-2-derived bNAbs, the V H 1-46 bNAbs reported to date have lower potencies and breadth, which limits their potential for clinical use (Bonsignori et al., 2016; Gao et al., 2014; Scheid et al., 2011) . For example, CH235.12, one of the best V H 1-46-derived CD4bs antibodies, is less broad and more than 10-fold less potent than the VRC01-class bNAb N6 when tested against a large panel of HIV-1 strains (Bonsignori et al., 2016) .
Accordingly, all CD4bs bNAbs that have advanced into clinical testing are members of the VRC01 class (3BNC117, N6, VRC01, and VRC07-523) ; Bar-On et al., 2018; Caskey et al., 2015 Caskey et al., , 2019 Cohen et al., 2018a; Crowell et al., 2019; Gaudinski et al., 2018 Gaudinski et al., , 2019 Gruell and Klein, 2018; Ledgerwood et al., 2015; Lynch et al., 2015a; Mayer et al., 2017; Mendoza et al., 2018; Riddler et al., 2018; Scheid et al., 2016) . However, although escape from VRC01 has been associated with a reduction in viral fitness (Lynch et al., 2015b) , the effects of VRC01class monotherapy are only transient and associated with emergence of viral escape variants Caskey et al., 2015; Horwitz et al., 2013; Klein et al., 2012; Lynch et al., 2015a; Scheid et al., 2016) .
Here we describe bNAb 1-18, a V H 1-46-derived CD4bs antibody that exceeds the potency and breadth of most classical V H 1-46-and V H 1-2-derived bNAbs. The structural basis of its high activity was revealed by a single-particle cryoelectron microscopy (cryo-EM) structure of a 1-18 Fab-BG505 SOSIP.664 Env trimer complex solved at 2.5-Å resolution. Of particular interest, compared with 3BNC117 and VRC01, the two most clinically advanced CD4bs bNAbs, 1-18 effectively restricts viral escape and maintains both neutralizing activity against VRC01-class escape variants and full viral suppression when tested in HIV-1 YU2 -infected humanized mice. Therefore, 1-18 is a highly promising candidate for antibody-mediated strategies to effectively treat and prevent HIV-1 infection.
RESULTS

Identification of Potent V H 1-46-Derived bNAbs
To identify individuals with elite HIV-1-neutralizing activity, we screened HIV-1-infected subjects. From each individual, purified serum or plasma immunoglobulin G (IgG) was tested for neutralizing activity in a TZM-bl cell assay against a multiclade screening panel of 12 HIV-1 pseudoviruses (deCamp et al., 2014; Sarzotti-Kelsoe et al., 2014;  Figure 1A ). We identified IDC561, a clade B-infected long-term non-progressor (Walker and Yu, 2013) , as ranking among the top 1% of a cohort of 2,274 individuals (HIV-1-neutralizing activity at a geometric mean IC 50 [50% inhibitory concentration] of 41.7 mg IgG/mL; Figures 1A and S1A-S1C). To characterize the epitope specificity of the IgG response, we performed neutralization fingerprinting and detected VRC01-like activity Figure S1D) . However, virus obtained from IDC561 was sensitive to 3BNC117 and N6, suggesting that the HIV-1-neutralizing antibodies in IDC561 differ from VRC01-class antibodies ( Figure S1E ).
To identify antibodies that accounted for the potent neutralizing activity of IDC561, we performed single-cell sorting of Env-reactive B cells that bound to native-like BG505 SOSIP.664 Sliepen et al., 2015) (0.08% of IgG + B cells) or to YU2 gp140 (Scheid et al., 2009; Yang et al., 2000) (0.72% of IgG + B cells) ( Figure 1B ). Using a new amplification strategy with primer sets optimized for precise detection of highly mutated IgG gene segments (OPT5/oPR; Kreer et al., 2019) , we obtained and analyzed 812 IgG heavy-chain sequences (BG505 SOSIP.664 , n = 445; YU2 gp140 , n = 367) ( Figure 1B) . Compared with the total IgG + B cell reservoir of IDC561, Envreactive B cells carried slightly longer CDRH3s (median length of 17 versus 16 amino acids, p < 0.001), had higher levels of somatic mutation (median V H gene nucleotide germline identity of 88.4% versus 95.3%, p < 0.001), and were enriched for the V H gene segments 1-46, 1-69, and 4-4 (Figures S1F-S1H). Among Env-reactive B cells, we identified 80 B cell clones with two or more members ( Figure 1B ).
Following production of monoclonal antibodies (Table S1) , binding of both BG505 SOSIP.664 and YU2 gp140 was detected by ELISA for 70% of the tested antibody clones ( Figure 1C ; Table  S2 ). The antibodies of most clones showed no or minimal neutralizing activity when analyzed against the 12-strain global panel, suggesting that they play a limited role in the serum activity of IDC561 ( Figure 1C ; Table S3A ). In contrast, all tested members (23 antibodies) of B cell clone 4 (comprising subclones 4.1-4.4) neutralized 92%-100% of viruses in the screening panel with remarkable potency (GeoMean IC 50 of 0.032-0.198 mg/mL; Figure 1D ; Table S3A (Table S1 ). Subclone 4.1 showed the highest breadth and potency and was characterized by a six-amino-acid CDRH1 insertion that lengthened the CDRH1 from 8 to 14 amino acids ( Figure 1D ; Tables S1 and S4). We conclude that antibodies of the V H 1-46-derived B cell clone 4 are highly potent, broadly active, and likely mediate the neutralizing serum activity of the elite neutralizer IDC561.
1-18: A CD4bs bNAb with Near-Universal Breadth and Outstanding Potency
We selected antibodies 561_01_18 and 561_01_55 (hereafter referred to as 1-18 and 1-55), two representative members of clone 4.1, for further analyses (Figure 2A ). Both antibodies are highly mutated, with heavy and light chain V gene germline nucleotide sequence identities of 68% and 78%-79%, respectively ( Figure 2A ; Table S4 ). Notably, the neutralizing activities of 1-18 and serum IgG of IDC561 against 42 pseudoviruses strongly correlated, suggesting that members of clone 4.1 are main contributors to the serum activity of IDC561 ( Figure S2A ). To determine binding of 1-18 and 1-55 to the BG505 SOSIP.664 trimer in the presence of other HIV-1 bNAbs, we performed competition ELISAs and detected interference with 3BNC117, N6, and VRC01 (Figures 2A; S2B ). However, compared with these VRC01-class CD4bs antibodies, a different binding pattern was detected for 1-18 and 1-55 when tested by ELISA against several Env proteins. For example, whereas 3BNC117, N6, and VRC01 bound similarly to YU2 gp120 , YU2 gp140 , and BAL gp140 and were reactive to the V 1 -V 3 loop-deficient gp120 variant RSC3 , bNAbs 1-18 and 1-55 showed lower (YU2 gp120, YU2 gp140 , and BAL gp140 ) or no (RSC3) binding to these proteins ( Figure S2C ). Therefore, 1-18 and 1-55 target the CD4bs but recognize this epitope differently than VRC01-class antibodies. We next evaluated the neutralizing activity of 1-18 in detail. In comparison with four bNAbs in advanced stages of clinical investigation (3BNC117, VRC01, 10-1074, and PGT121), 1-18 demonstrated superior activity with high potency (GeoMean IC 50 of 0.035 mg/mL, GeoMean IC 80 [80% inhibitory concentration] of 0.155 mg/mL) against all viruses of the 12-strain global screening panel (deCamp et al., 2014;  Figure 2B ; Table S3A ). Although 1-18 competed with other CD4bs bNAbs for binding to BG505 SOSIP.664 by ELISA, no reduction in neutralizing activity was detected when 1-18 and 3BNC117 were combined ( Figure S2D ). To confirm the results of the screening panel, we evaluated the activity of 1-18 on extended pseudovirus panels. Overall, 1-18 ranked among the best bNAbs that are currently available ( Figure 2C ). When tested against a 119-strain multiclade panel, 1-18 showed highly potent activity (GeoMean IC 50 of 0.048 mg/mL, GeoMean IC 80 of 0.183 mg/mL) with a breadth of 97% ( Figure 2D ; Table S5A ). In addition, 1-18 demonstrated high potency (GeoMean IC 50 of 0.074 mg/mL, GeoMean IC 80 of 0.279 mg/mL) and breadth (90%) when tested against a 100-strain clade C panel (Table  S5B ). Finally, we determined the activity of 1-18 against culture-derived primary HIV-1 strains that are generally more difficult to neutralize than pseudoviruses (Cohen et al., 2018b) . Against viruses obtained from 51 HIV-1-infected individuals, 1-18 demonstrated higher breadth and/or potency (GeoMean IC 50 of 0.56 mg/ mL, GeoMean IC 80 of 1.57 mg/mL, 96% breadth) than 3BNC117, VRC01, 10-1074, and PGDM1400 ( Figure 2E ; Table S5C ) and was superior to the near-pan-neutralizing V H 1-2-derived CD4bs bNAb N6 (Huang et al., 2016a;  Figure 2F ; Table S5C ).
We conclude that 1-18 is a highly broad and potent V H 1-46derived antibody that rivals or exceeds the activity of CD4bs bNAbs described to date.
1-18 Targets the CD4bs and Regions of the Adjacent gp120 Protomer
To characterize Env recognition by the 1-18 family of bNAbs, we solved cryo-EM structures of 1-18 and 1-55 Fabs in complex with soluble native-like Env trimers and the V3-targeting bNAb 10-1074 at resolutions of 2.5 Å (1-18 complexed with BG505 SOSIP.664 ) and 3.9 Å (1-55 complexed with RC1, a designed immunogen that is a derivative of BG505 SOSIP.664 ; Escolano et al., 2019) (Figures 3A and S3; Table S6 ). Notably, at 2.5-Å resolution, the 1-18 complex is the highest resolution view yet obtained of an HIV-1 Env trimer ( Figure S3A ; Table S6 ). Both complexes contained three 1-18 family Fabs and three 10-1074 Fabs interacting with three-fold symmetry with a SOSIP-Env trimer. 1-18 and 1-55 recognized the CD4bs similarly to other V H 1-46-derived bNAbs, including 8ANC131 and CH235.12 (Bonsignori et al., 2016; Zhou et al., 2015) , with interactions encompassing contacts with the N276 gp120 and N197 gp120 glycans, the CD4bs loop via the CDRH2, the V5 loop via the CDRH2, and loop D via the CDRL3 (Figures 3A, 3B, S4A, and S4B). However, in addition, 1-18 contacts Env by residue F54 HC , which is buried in the gp120 'Phe43 pocket', and by residue R64 HC , which makes a salt bridge with V5 residue D457 gp120 ( Figure S4B ). These interactions mimic analogous gp120 contacts made by CD4 residues F43 CD4 and K35 CD4 , respectively, and the V H 1-2-derived bNAb N6 also buries an aromatic residue (Y54 HC ) in the 'Phe43 pocket' (Huang et al., 2016a; Kwong et al., 1998;  Figure S4B ).
In addition to the canonical V H 1-46 contacts, 1-18 contains a six-residue insertion in its CDRH1, resulting in a negatively charged 25 DDDPYTDDD 33 motif that interacts with the adjacent (B) Activity of 1-18 against the global panel compared with bNAbs in advanced stages of clinical testing, individually sorted by increasing IC 50 values for each bNAb. Data for 3BNC117, VRC01, 10-1074, and PGT121 were derived from CATNAP (Yoon et al., 2015) . (C) Activity of 1-18 compared with a selection of bNAbs against an identical set of 109 pseudovirus strains (Yoon et al., 2015) . For N6, neutralization data were determined in the same laboratory as for 1-18. (D) Activity against the 119-pseudovirus multiclade panel. Data for 3BNC117, VRC01, 10-1074, and PGT121 were derived from CATNAP (Yoon et al., 2015) . (cartoon representation) and Env, with primary gp120 shown in light gray and secondary gp120 (gp120 2 ) shown in dark gray. Protein regions that are contacted by 1-18 are shown as colored surfaces, and glycans are shown as sticks. gp120 protomer ( Figures 3B-3D ). At the adjacent protomer, four Asp residues in the 1-18 CDRH1 (D25 HC , D27 HC , D31 HC , and D32 HC ) plus T30 HC form coordinated interactions around the highly conserved Env residue K207 gp120 ( Figure 3C ). In addition, the increased length of the 1-18 CDRH1 places Y29 HC in a position to interact with residues in the V3 loop on the adjacent protomer (S306 gp120 , R308 gp120 , A316 gp120 , and Y318 gp120 ) (Figure 3C) . Although not all of the Asp residues in the 1-18 CDRH1 contact positively charged residues on gp120, the Asp-rich insertion may have been selected to carry an overall negative charge that is electrostatically attracted to the positively charged patch within the V3 loop on the adjacent protomer ( Figure 3D ), which could drive formation of an initial Env-antibody complex (Schreiber et al., 1996) . Although other CD4bs bNAbs include Asp-containing insertions in either the CDRH1 or heavy-chain framework region 3 (FWRH3) that interact with the positively charged gp120 patch (Lee et al., 2017; Liu et al., 2019; Xu et al., 2018;  Figure S4C ), the number of Asp in the CDRH1 of 1-18 and the extent of their interaction to Env have not been described before. Notably, gp120 residues contacted by the 1-18 CDRH1 contribute to the CD4 and/or co-receptor binding sites Rizzuto et al., 1998; Shaik et al., 2019) , and most residues are highly conserved ( Figure 3C ). Demonstrating their importance for viral function, mutations in some of these residues have been shown to substantially reduce infectivity (de Taeye et al., 2015; Liu et al., 2017) .
To evaluate the relevance of the CDRH1 insertion for the neutralizing activity of 1-18, we engineered 1-18Dins, a 1-18 variant lacking the insertion. When tested against the 12-strain global panel, 1-18Dins showed significantly reduced potency compared with 1-18 (GeoMean IC 50 values of 0.114 mg/mL and 0.035 mg/mL [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] , respectively; p = 0.012; Table  S3B ). In addition, we investigated antibody 561_02_12 (referred to as 2-12), a member of clone 4 that developed in individual IDC561 but does not have a CDRH1 insertion. Compared with 1-18, antibody 2-12 showed lower breadth on extended pseudovirus panels (119-strain multiclade panel: 1-18, 97% breadth; 2-12, 87% breadth; 100-strain clade C panel: 1-18, 90% breadth; 2-12, 74% breadth; Tables S5A and S5B). Analysis of the neutralization panel data indicated reduced potency of 2-12 against viruses carrying H364 gp120 in the CD4 binding loop. In contrast, 1-18 is less affected by this variation, suggesting a higher tolerance for structural variations in this site.
Compared with the epitopes of the CD4bs bNAbs 3BNC117 and VRC01 (Lee et al., 2017; Stewart-Jones et al., 2016 ), 1-18 and 1-55 bury more surface area on both the primary gp120 epitope and the adjacent protomer, another potential mechanism for their increased breadth and potency  Figure 3E ). Finally, the slightly higher neutralizing activity of 1-18 compared with 1-55 might be explained by variations in glycan accommodation ( Figure S4D ). We conclude that 1-18 mediates exceptional HIV-1-neutralizing activity by an increase in buried surface on gp120, primarily through increased interprotomer contacts mediated by its unique CDRH1.
1-18 Is Not Affected by Typical VRC01-Class Escape Mutations
To determine how known Env escape mutations affect the neutralizing activity of 1-18, we evaluated the sensitivity of HIV-1 YU2 pseudovirus variants. As expected, removal of potential N-linked glycosylation sites (PNGSs) in the V2 (N160 gp120 ) and V3 (N301 gp120 , N332 gp120 ) loops mediated resistance to the V1/V2directed bNAbs PG16 and PDGM1400 and the V3-directed bNAbs 10-1074 and PGT128, respectively Pejchal et al., 2011; Sok et al., 2014; Walker et al., 2009 Walker et al., , 2011 , but did not affect neutralization by 1-18 or other CD4bs bNAbs ( Figure 4) . Similarly, removal of a PNGS adjacent to the CD4bs (N276 gp120 ) reduced sensitivity to the gp120-gp41 interface bNAb 8ANC195 (Scharf et al., 2014) but had no effect on 1-18 ( Figure 4 ). V H -restricted CD4bs bNAbs typically interact with loop D residues N279 gp120 and/or N280 gp120 , and changes in these residues have been associated with viral rebound from CD4bs therapy (Diskin et al., 2013; Horwitz et al., 2013; Julg et al., 2017; Klein et al., 2012; Lynch et al., 2015a) . When we tested HIV-1 YU2 variants with mutations at these residues, we observed reduced or abrogated sensitivity to VRC01-class bNAbs and to the V H 1-46-derived CD4bs bNAb 8ANC131 ( Figure 4 ). In contrast, these mutations had no or only minimal effects on 1-18 ( Figure 4 ). Maintained neutralizing activity against these variants might be mediated by increased contacts of 1-18's extended CDRH1 that formed compensatory interactions, alleviating the necessity for loop D contacts normally required by CD4bs antibodies. Additionally, the portion of 1-18's CDRL3 that contacts loop D utilizes a glycine-rich 92 GGT 94 motif rather than the 92 SST 94 motif in 8ANC131. This could accommodate mutations in loop D (N279K, N280Y) through increased flexibility. Finally, the 7-Å shift in CDRL2 location between 1-18 and 8ANC131 could allow greater accommodation of a glycan at N279 gp120 in two HIV-1 YU2 variants (A281T and T278I/A281T).
Mutations in the b23 and b24 strands surrounding the V5 loop (gp120 residues 451-471) were associated with viral resistance against 8ANC131 but were tolerated by 1-18 ( Figure 4 ). V5 loop residue D457 gp120 interacts with 1-18 R64 HC , a somatic mutation from the V H 1-46 germline that is present in 1-18 but not in 8ANC131. We hypothesize that the R64 HC -D457 gp120 salt bridge is a crucial interaction between 1-18 and gp120 that potentially allows it to tolerate common routes of Env escape within the V5 loop.
We conclude that 1-18 maintains full activity against viruses carrying mutations associated with viral resistance against other CD4bs bNAbs in vitro.
Mutational Antigenic Profiling of 1-18 Reveals Restricted HIV-1 Escape
To identify potential pathways of viral escape from 1-18, we used mutational antigenic profiling with libraries of HIV-1 BG505 variants containing all single amino acid substitutions within the ectoand transmembrane domains of Env ( Figure S5 ; Dingens et al., 2017; Haddox et al., 2018) . In this assay, the effects of Env mutations on antibody resistance are quantitatively determined by deep sequencing of cells that become infected in the presence versus the absence of an antibody.
1-18 only selected escape mutants at a small number of residues, all of which were outside of the canonical CD4bs. In contrast to 3BNC117 and VRC01 , we observed no statistically significant escape from 1-18 in loop D and the CD4 binding loop (Figures 5A-5C and S5). Rather, 1-18-mediated selection was localized to the V3 loop and the stem of the V1/V2 loop of gp120 ( Figure 5C ). Among the four sites of significant escape, three residues (K207 gp120 , R304 gp120 , and Y318 gp120 ) interact with the CDRH1 of 1-18 ( Figure 5C ). The fourth residue, C119 gp120 , generally forms a disulfide bond with C205 gp120 at the stem of the V1/V2 loop. Thus, mutations at residue C119 gp120 may reduce 1-18 accessibility to the highly conserved K207 gp120 by disordering the V1/V2 loop structure (Leonard et al., 1990; van Anken et al., 2008) .
Mutational antigenic profiling allows identification of the strongest escape mutations for each antibody (Figures 5A-5C and S5E). Importantly, although VRC01 escape mutations were associated with a 3-to more than 175-fold increase in the antibody IC 50 values for HIV-1 BG505 pseudovirus variants , the effects were much less pronounced for potential A   C119  V120  K121  N195  C196  N197  T198  S199  P206  K207  V208  S209  E275  N276  I277  T278  N279  N280  A281  K282  N283  R304  K305  S306  I307  R308  I309  G312  P313  G314  Q315  A316  F317  Y318  A319  T320  G366  G367  D368  L369  E370  V371  T372  T373  R456  D457  G458  G459 S460 T461 * * * * 1-18 escape mutants ( Figure 5D ). When we evaluated HIV-1 BG505 pseudoviruses carrying single mutations at the six residues with the highest level of 1-18-mediated selection, the sensitivity to 1-18 was reduced by less than 2.3-fold for 5 of the 6 tested viruses ( Figure 5D ). The sixth virus, carrying an A316E mutation, showed a 3.2-fold decrease in sensitivity (IC 50 increased to 0.098 mg/mL) ( Figure 5D ). Therefore, all tested potential escape variants remained highly 1-18-sensitive when evaluated as pseudoviruses. To determine the ease of viral escape, we compared the effects of the 40 strongest mutations from antigenic profiling of 1-18 with those of VRC01, 3BNC117, 10-1074, or the combination of 3BNC117 and 10-1074 . The levels of escape observed for 1-18 were lower than those for the single bNAbs and similar to the combination of 3BNC117 and 10-1074 ( Figure 5E ). Overall, mutational antigenic profiling of 1-18 revealed a strong limitation of HIV-1 BG505 escape via single amino acid mutations, with no evidence of selection at the canonical CD4bs that is critical for resistance against VRC01-class bNAbs.
Full Suppression of Viremia by 1-18 Monotherapy In Vivo
To determine the antiviral activity of 1-18 in vivo, we used HIV-1 YU2 -infected humanized mice that can maintain stable viremia with a rate of HIV-1 diversification similar to what is observed in humans (Gruell and Klein, 2017; Ince et al., 2010; Klein et al., 2012; Zhang et al., 2002;  Figure S6A ).
Following a 1-mg loading dose of antibody administered subcutaneously (s.c.), we treated HIV-1 YU2 -infected mice (n = 6-10 per group) twice a week with s.c. injections of 0.5 mg per bNAb for 4-8 weeks ( Figure 6A ). Treatment with 3BNC117, VRC01, or the combination of both bNAbs resulted in mean viral load reductions of 0.5, 0.5, and 0.7 log 10 copies/mL, respectively. However, these effects were only transient, and viral rebound occurred within the first 2 weeks in most animals, indicating rapid viral escape ( Figure 6A ). Indeed, when plasma singlegenome sequencing (SGS) was performed at week 4 after the start of treatment, 79 of 82 isolated viruses from 16 mice showed mutations in the VRC01 and 3BNC117 target sites in loop D and/or the b23/ V5 loop regions of gp120 (Figures 6B and 7A; Tables  S7A-S7C) .
In contrast to the transient effects of 3BNC117 and VRC01, monotherapy of HIV-1 YU2 -infected humanized mice with 1-18 resulted in sustained viral suppression over a period of 8 weeks in all treated animals (average drop of 1.7 log 10 copies/mL; . Moreover, in all but one mouse, viremia dropped to levels below the level of quantitation (384 copies/mL) by day 35. From the one mouse (1069) that had quantifiable levels of viremia but was suppressed (drop of 1.9 log 10 copies/mL), we analyzed HIV-1 env sequences at week 4 ( Figures 6A and 6B ). We detected no recurrent mutations at contact residues of 1-18 or typical CD4bs bNAbs, and pseudoviruses derived from these sequences remained sensitive to 1-18 ( Figure 6B ; Table  S7D ). These results were confirmed in an independent repeat experiment for 1-18 as well as for 1-55, another member of clone 4.1 ( Figure S6B ). Although five of six 1-18-treated mice in this experiment were fully suppressed, one mouse (1730) continued to show high HIV-1 RNA copy numbers ( Figure S6B ). However, all env sequences obtained from this mouse carried large V4 loop deletions as well as early stop codons ( Figure S6C ). Thus, despite detectable rebound of viremia in 1 of 18 mice treated with 1-18 or 1-55, no functional escape viruses were observed by SGS and evaluation of pseudoviruses.
Effective clinical application of bNAbs depends on favorable safety and pharmacokinetic profiles. Following a single injection of 1-18 or 1-55, their decline in serum of immunodeficient mice was slower compared with VRC01-class bNAbs and more similar to 10-1074, which has a longer half-life than 3BNC117 and VRC01 in humans (Bar-On et al., 2018; Caskey et al., 2015 Caskey et al., , 2017 Ledgerwood et al., 2015; Lynch et al., 2015a; Mendoza et al., 2018;  Figure S6D ). In addition, whereas some bNAbs demonstrate binding to self-antigens (Haynes et al., 2005) , we found no indication for autoreactivity of 1-18 or 1-55 when tested against HEp-2 cells ( Figure S6E ).
In summary, we conclude that 1-18 has exceptional antiviral in vivo activity against HIV-1 YU2 . This activity is superior to the CD4bs antibodies 3BNC117 and VRC01, which are currently being evaluated in clinical trials. Importantly, single bNAb therapy with 1-18 is sufficient to effectively prevent development of viral escape variants that rapidly emerge during HIV-1 YU2 monotherapy with other bNAbs Klein et al., 2012) .
1-18 Overcomes VRC01-Class Escape Mutations In Vivo
To confirm that mutations occurring during 3BNC117 and/or VRC01 therapy conferred antibody resistance, we generated 30 pseudoviruses derived from day 28 env sequences of 11 VRC01-class-treated mice. We found 23 viral variants that were fully resistant to the administered antibodies (IC 50 > 25 mg/mL) or showed increased VRC01-class resistance (>5fold increase in IC 50 values). Notably, however, all of these (2019) . Regions in gray are detailed in (B). (B) HIV-1 BG505 escape profiles, with letter heights indicating the excess fraction surviving for each mutation. Circles indicate HIV-1 BG505 residues interacting with [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] . Asterisks indicate residues with statistically significant antibody escape. (C) The BG505 SOSIP.664 trimer, colored according to the maximum excess fraction surviving 1-18 at each site, with 1-18 shown in blue. In the inset, structurally defined contacts are shown as spheres, and the CDRH1 is highlighted by the rectangle. Interactions of the CDRH1 with the adjacent gp120 protomer are indicated on the right. (D) The top row indicates IC 50 of 1-18 against the BG505 T332N pseudovirus, and the panels show fold change in IC 50 for BG505 T332N pseudovirus variants with mutations in the six residues showing the highest excess fraction surviving 1-18 neutralization. Circles indicate interactions as in (B). (E) Excess fraction surviving for the 40 mutations with the largest effect sizes for each antibody. Circles indicate the number of nucleotide changes required for the respective amino acid mutation. See also Figure S5 .
pseudoviruses remained sensitive to 1-18 in vitro ( Figure 7B ; Table S7 ).
To determine whether 1-18 can overcome escape from VRC01-class bNAbs in vivo, we added bNAb 1-18 therapy (1-mg loading dose s.c. followed by 0.5 mg s.c. twice weekly) to 3BNC117-and/or VRC01-pretreated animals while continuing 3BNC117 and/or VRC01 administrations ( Figure 7C ). Despite circulating VRC01-class-resistant viral variants, 1-18 effectively reduced viremia and maintained viral suppression in 17 of 18 mice ( Figure 7C ). Following interruption of bNAb therapy, viral rebound occurred in all fully suppressed mice when Envreactive antibody plasma concentrations declined to a median See also Figure S6 and Table S7 . of 0.1 mg/mL ( Figure 7D ). To determine whether declining 1-18 levels resulted in selection of 1-18-resistant escape variants, we performed plasma SGS of rebound viruses 8 weeks after treatment interruption (day 114) ( Figure 7E ). Although we found novel mutations compared with day 0 and day 28 in 39 of 60 sequences from 12 mice, there was no recurrent pattern of mutations that developed after 1-18 therapy ( Figure 7E ). Indeed, all 20 sequences tested as pseudoviruses were demonstrated to be fully sensitive to 1-18 ( Figure 7E ; Table S7 ). We conclude that bNAb 1-18 effectively overcomes VRC01class resistance in vivo and maintains viral suppression without the development of 1-18-resistant HIV-1 YU2 variants.
DISCUSSION
Implementation of HIV-1-neutralizing antibodies for clinical practice requires antibodies with specific characteristics. These include safety, a favorable pharmacokinetic profile, and broad and highly potent neutralizing activity to effectively target the remarkable diversity of HIV-1 (Caskey et al., 2019) . In addition, as for any drug against HIV-1, viral escape represents one of the biggest challenges for clinical application. This became evident when (1) single bNAbs were used for therapy and HIV-1 resistance developed within a few weeks Caskey et al., 2015 Caskey et al., , 2017 Klein et al., 2012; Lynch et al., 2015a; Scheid et al., 2016) , and (2) antibody combinations resulted in improved viral control by preventing early development of resistance (Bar-On et al., 2018; Klein et al., 2012; Mendoza et al., 2018) . Therefore, restriction of HIV-1 escape will be an antibody-dependent feature of utmost importance for successful bNAb applications.
VRC01-class antibodies targeting the functionally critical CD4bs have broad and potent neutralizing activity but fail to prevent viral escape in vivo Caskey et al., 2015; Horwitz et al., 2013; Klein et al., 2012; Lynch et al., 2015a; Scheid et al., 2016) . Through a combination of functional in vitro mapping and in vivo therapy of HIV-1-infected humanized mice, we demonstrated that the V H 1-46-derived CD4bs bNAb 1-18 effectively restricts development of HIV-1 resistance. Contrasting other CD4bs bNAbs, we did not identify single amino acid mutations resulting in 1-18 resistance in two viral strains of different clades (BG505, clade A; YU2, clade B). Most importantly, in the setting of viral replication and diversification in HIV-1 YU2 -in-fected humanized mice, 1-18 monotherapy resulted in effective and sustained viral suppression. Notably, the in vivo activity of 1-18 was not affected by VRC01-class-resistant viral variants. Thus, despite mutations in up to two sites associated with escape from CD4bs antibodies, 1-18 effectively suppressed viremia and restricted the development of additional escape mutations.
In our cryo-EM analysis of a 1-18-BG505 complex, the highest-resolution HIV-1 Env trimer structure obtained to date (2.5 Å ), the details of 1-18 recognition of Env were determined. The structure demonstrated that 1-18 combines favorable features found in potent V H 1-2 bNAbs that likely contribute to its exceptional potency and breadth. These characteristics include (1) an aromatic residue that mimics residue Phe43 of CD4 to target the 'Phe43 gp120 pocket', as seen in bNAb N6 (Huang et al., 2016a) ; (2) contacts with the adjacent gp120 protomer, as seen for bNAb 3BNC117 (Lee et al., 2017; Lyumkis et al., 2013) but with increased buried surface area (via its six-residue insertion in CDRH1); and (3) a larger buried surface area on gp120 than other V H 1-2 bNAbs: 1,530 Å 2 compared with 1,260 Å 2 (VRC01) and 1,290 Å 2 (3BNC117). Finally, 1-18's unique mode of binding enables it to make additional contacts with conserved residues on gp120 not found in other CD4bs bNAbs, allowing 1-18 to rely less on classical CD4bs bNAb contacts and making viral escape more difficult. These characteristics may explain 1-18's exceptional potency, breadth, and resistance to viral escape. Notably, functional antigenic mapping demonstrated that 1-18-mediated selection was focused on contact residues within the CDRH1. Moreover, the lack of the CDRH1 insertion in antibodies 1-18Dins and 2-12 was associated with reduced neutralizing activity compared with 1-18.
Despite the remarkable neutralization breadth of 1-18 (covering 256 of 271 evaluated primary viruses and pseudoviruses), a small number of viruses was found to be 1-18 resistant. However, sequence analysis did not identify single residues that were associated with 1-18 resistance. In addition, we analyzed viruses from individual IDC561, from whom 1-18 was identified. Although viremia was controlled in the absence of ART for more than 15 years, it was detectable by the time of 1-18 isolation. Indeed, viruses obtained at this time showed resistance against 1-18 and clonal members (Figure S7) . Remarkably, however, their CD4bs sequences presented with highly infrequent amino acid residues ( Figure S7 ). (C) Addition of 1-18 treatment on day 28 to HIV-1 YU2 -infected humanized mice that showed viral rebound during 3BNC117, VRC01, or 3BNC117+VRC01 therapy ( Figure 6A ). The previous treatment regimen was continued. HIV-1 RNA plasma copies are shown at the top and log 10 viral load changes compared with baseline (day 28) at the bottom. Dashed lines in the top panels indicate the quantitation limit of accuracy (384 copies/mL), and data points in white indicate viral loads of less than 384 copies/mL. Red lines show average log 10 viral load changes compared with baseline (day 28). (D) HIV-1 RNA plasma copies (left y axis) and plasma bNAb levels determined by BG505 SOSIP.664 -ELISA (right y axis) after interruption of bNAb therapy on day 56 as indicated in (C). Only mice that could be followed for 58 days are included. Dashed lines indicate the HIV-1 RNA quantitation limit of accuracy (384 copies/mL). White circles show viral loads of less than 384 copies/mL, and gray circles indicate antibody levels of less than 1 mg/mL. (E) Plasma SGS-derived env sequences obtained on day 114. Black bars indicate amino acid mutations compared with the YU2 wild-type found previously; red bars indicate mutations only found on day 114 within individual mice. Numbering is according to HIV-1 YU2 . Boxes indicate IC 50 values of 1-18 against the corresponding pseudoviruses (right). See also Table S7. For example, among 2,351 clade B env sequences in the Los Alamos HIV Sequence Database, only 0.8% carried a glycine at the loop D residue 281 gp120 , and not a single virus had a glutamic acid at position 474 gp120 ( Figure S7) . Similarly, uncommon amino acids were found in other loop D (282 gp120 ) and V5 loop (471 gp120 ) positions as well as at residue 208 gp120 , which neighbors K207 gp120 that strongly interacts with the CDRH1 of 1-18 ( Figure S7 ). Taking the results from profiling escape pathways in vitro together with the lack of viral escape in humanized mouse experiments, the occurrence of multiple uncommon amino acid residues in 1-18-resistant viruses suggests a restricted escape pathway from 1-18 that may require accumulation of multiple rare mutations.
Current strategies to combine bNAbs are based on the use of antibodies targeting non-overlapping epitopes (Bar-On et al., 2018; Barouch et al., 2013; Huang et al., 2016b; Klein et al., 2012; Mendoza et al., 2018; Shingai et al., 2013; Xu et al., 2017) . To this end, the combination of 1-18 with bNAbs targeting other epitopes (e.g., the MPER antibody DH511.2_K3, which neutralizes 100% of tested clade C viruses; Williams et al., 2017) may be a promising option. Because the most potent known CD4bs bNAbs are of the VRC01-class, synergistic effects by combinations of these antibodies are not expected. However, given their different binding, neutralization, and escape patterns, a combination of 1-18 with VRC01-class CD4bs bNAbs may be highly beneficial. The capacity of 1-18 to overcome VRC01-class escape mutations in vivo as well as a calculated breadth of more than 99% when 1-18 is combined with VRC01-class bNAbs (e.g., N6 or 3BNC117) offers new possibilities of bNAb combinations, such as a dual anti-CD4bs therapy. Finally, CD4bs bNAbs have been demonstrated to induce escape variants with reduced viral fitness (Lynch et al., 2015b; Otsuka et al., 2018; Sather et al., 2012) . Applying double CD4bs-targeting pressure may force the virus to more extensively mutate this functionally critical epitope and, therefore, result in impaired viral variants and prolonged viral control.
In summary, by combining outstanding neutralizing activity and a high barrier for viral escape, 1-18 provides a new option for highly effective treatment and prevention of HIV-1 infection.
STAR+METHODS
Detailed methods are provided in the online version of this paper and include the following: 
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LEAD CONTACT AND MATERIALS AVAILABILITY
Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Florian Klein (florian.klein@uk-koeln.de). Nucleotide sequences of all generated antibodies were deposited at GenBank, and expression plasmids for 1-18, 1-55, 2-12, and clonal members will be shared upon request.
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Human Subjects Blood and leukapheresis samples were obtained under protocols approved by the Institutional Review Board of the University of Cologne (protocols 13-364 and 16-054) and the local IRBs. All participants provided written informed consent. Participants of the neutralization screening cohort are recruited at hospitals and/or private practices in Germany (Cologne, Essen, and Frankfurt), Cameroon (Yaoundé ), Nepal (Kathmandu), and Tanzania (Mbeya). At the time of leukapheresis, IDC561 was a 48-year-old male who was diagnosed with HIV-1 infection 21 years earlier. He was recruited at the University Hospital Cologne. PBMCs for bulk viral outgrowth cultures were obtained from individuals recruited in Germany (Cologne).
Mouse Models
NOD.Cg-Rag1 tm1mom Il2rg tm1Wjl /SzJ (NRG) mice were purchased at The Jackson Laboratory and bred and maintained at the Decentralized Animal Husbandry Network (Dezentrales Tierhaltungsnetzwerk) of the University of Cologne under specific pathogen-free (SPF) conditions with 12-hour light/dark cycles. For breeding purposes, mice were provided with ssniff 1124 breeding feed; for experimental purposes, mice were provided with ssniff 1543 maintenance feed. Humanized mice were generated as previously described with modifications . In brief, human CD34 + hematopoietic stem cells were isolated from cord blood and perfused placental tissues using CD34 microbeads (Miltenyi Biotec). Collection of cord blood and placental tissues was conducted under a protocol approved by the Institutional Review Board of the University of Cologne (16-110), and all donors provided written informed consent. NRG mice were sublethally irradiated within 5 days of birth and intrahepatically injected with purified human CD34 + stem cells 4 to 6 hours later. Success of humanization was determined approximately 12 weeks later by FACS analysis of blood for human PBMCs. All mouse experiments were authorized by the State Agency for Nature, Environmental Protection, and Consumer Protection North Rhine-Westphalia (LANUV).
Cell Lines
HEK293T cells (American Type Culture Collection) were maintained at 37 C and 5% CO 2 in Dulbecco's Modified Eagle Medium (DMEM, Thermo Fisher) supplemented with 10% fetal bovine serum (FBS, Sigma-Aldrich), 1 mM sodium pyruvate, 2 mM L-glutamine, and 1x antibiotic-antimycotic (all from Thermo Fisher). TZM-bl cells (Platt et al., 1998) were maintained at 37 C in 5% CO 2 in DMEM supplemented with 10% FBS, 1 mM sodium pyruvate, 2 mM L-glutamine, 50 mg/ml gentamicin (Merck), and 25 mM HEPES (Millipore). 293-6E cells (National Research Council of Canada) were maintained at 37 C and 6% CO 2 in FreeStyle Expression Medium (Thermo Fisher) and kept under constant shaking at 90-120 rpm. Expi293 cells (Thermo Fisher) were maintained at 37 C and 8% CO 2 in Expi293 Expression medium (Thermo Fisher) and kept under constant shaking at 130 rpm. CHO cells were maintained at 37 C and 5% CO2 in ProCHO-5 media (Lonza) supplemented with 0.1 M HEPES, 1x GlutaMAX, 1x MEM NEAA, 1 mM sodium pyruvate, and 0.5 mg/ml hygromycin B (all from Thermo Fisher). SupT1-R5 cells (Didigu et al., 2014) were maintained at 37 C and 5% CO 2 in RPMI 1640 supplemented with 300 mg/l L-glutamine (Thermo Fisher), 10% FBS (Sigma-Aldrich), and 1% penicillin/streptomycin (Thermo Fisher). The sex of HEK293T, TZM-bl, 293-6E, Expi293, and CHO cell lines is female, and the sex of SupT1-R5 cells is male. Cell lines were not specifically authenticated. 
METHOD DETAILS
Clinical Samples
Peripheral blood mononuclear cells (PBMCs) were isolated by density-gradient centrifugation and stored at À150 C in 90% FBS and 10% DMSO (Sigma-Aldrich) until further use. Plasma and serum samples were stored at À80 C until further use.
Serum and Plasma IgG Isolation
Serum and plasma samples were heat-inactivated (56 C for 40 min) and incubated with Protein G Sepharose (GE Life Sciences) overnight at 4 C. IgGs were eluted from Protein G in chromatography columns using 0.1 M glycine (pH = 3.0) and buffered in 1 M Tris (pH = 8.0). Subsequently, buffer exchange to PBS and antibody concentration was performed using Amicon 30 kDa spin membranes (Millipore). Purified IgGs were stored at 4 C until further use.
Single Cell Sort B cells were isolated from PBMCs using the Pan B Cell Isolation Kit, B Cell Isolation Kit II, or IgG + Memory B Cell Isolation Kit (Miltenyi Biotec). Isolated cells were labeled with anti-human CD19-AF700 (BD), anti-human IgG-APC (BD), DAPI (Thermo Fisher), and the respective HIV-1 Env bait for 30 minutes on ice. BG505 SOSIP.664 -GFP or biotinylated YU2 gp140 that was labeled with Streptavidin-PE (BD) were used as HIV-1 Env baits. Env-reactive CD19 + IgG + DAPIsingle cells were sorted into 96-well plates containing 4 ml of lysis buffer (0.5x PBS, 10 mM DTT (Thermo Fisher), 2 U/ml RNasin (Promega), and 1 U/ml RNaseOUT (Thermo Fisher)) per well using a BD FACSAria Fusion. Plates were stored at À80 C until further use.
Single Cell cDNA Synthesis and PCR Sorted cells were incubated with 0.75 ml Random Hexamer Primer (Thermo Fisher), 0.5 ml NP-40 (Thermo Fisher), and 5.6 ml RNasefree H 2 O for 1 min at 65 C. Subsequently, 3 ml of 5x RT Buffer (Thermo Fisher), 0.5 ml dNTPs mix (25 mM, Thermo Fisher), 1 ml DTT (100 mM, Sigma Aldrich), 2.05 ml of RNase-free H 2 O, 0.1 ml RNasin (40 U/ml, Promega), 0.1 ml RNaseOUT (40 U/ml, Promega), and 0.25 ml Superscript IV (200 U/ml, Thermo Fisher) were added and samples were incubated at 42 C for 10 min, 25 C for 10 min, 50 C for 10 min, and 94 C for 5 min. Antibody sequences for single cell analysis were amplified by semi-nested PCRs using Platinum Taq DNA Polymerase or Platinum Taq Green Hot Start DNA Polymerase (Thermo Fisher) and previously described primers, including the novel OPT5/oPR-primer set optimized for detection of highly mutated IgG sequences , using the OPT5/oPRprimer mix and CG_RT 5 0 -AGGTGTGCACGCCGCTGGTC (Ozawa et al., 2006) for the 1 st PCR, and the OPT5/oPR-primer mix and IgG_Internal RT 5 0 -GTTCGGGGAAGTAGTCCTTGAC (Tiller et al., 2008) for the 2 nd PCR. First-round PCR was run at 94 C for 2 min; followed by 50 cycles of 94 C for 30 s, 55 C for 30 s, and 72 C for 55 s. Second-round PCR was run at 94 C for 2 min; followed by 50 cycles of 94 C for 30 s, 55 C for 30 s, and 72 C for 45 s. Second-round PCR products were sequenced by Sanger sequencing and used for further sequence analyses.
Antibody Sequence Analysis
Sequences with a mean Phred score R 28 and a minimal length of 240 nucleotides were annotated with IgBLAST (Ye et al., 2013) and trimmed from framework region (FWR) 1 of the variable region to the end of the J gene. Base calls with a Phred score < 16 were masked and sequences with > 15 masked nucleotides, frameshifts, or stop codons were excluded from further analyses. To analyze the sequences for potential clonalities, all productive heavy chain sequences were grouped by identical V genes and the pairwise Levenshtein distance of their CDRH3s was determined. Individual sequences were grouped into clones when they shared the same V gene and had a minimal CDRH3 identity of 75%. After 10 rounds with a randomized input of sequences, the result that yielded the lowest number of unassigned (non-clonal) sequences was selected for further analyses. All clones were re-validated manually by the investigators in order to identify shared mutations. Sequences that were initially assigned to different clones but shared the same VDJ genes and amino acid and/or silent nucleotide mutations were subsequently grouped into subclones. Nucleotide sequence identity to germline was calculated using IgBLAST. The maximum-likelihood phylogenetic tree in Figure 1D was generated using nucleotide sequences of heavy-chain V genes (FWRH1-FWRH3) of subclones 4. 1, 4.2, 4.3, and 4 .4 (n = 86 sequences) and of the IGHV1-46*01 Homo sapiens allele (GenBank X92343.1). All sequences were aligned using ClustalW (Geneious R10; cost matrix:
IUB; gap open cost: 15; gap extend cost: 6.66) and the maximum-likelihood phylogenetic tree was calculated using PhyML with 1,000 bootstrap replicates (Guindon et al., 2010 ) (substitution model: general time reversible [GTR]; Geneious R10). The best-scoring tree was then rooted to IGHV1-46*01.
Antibody Cloning and Production
For cloning of single cell-derived antibodies, the 1 st PCR product of single cell-PCR was used as template and amplified using Q5 Hot Start High Fidelity DNA Polymerase (New England Biolabs) and specific forward-and reverse primers that resembled the respective nucleotide sequence of the V-and J-regions (Tiller et al., 2008) with expression vector overhangs for subsequent sequence and ligation independent cloning (SLIC). PCR was run at 98 C for 30 s; 35 cycles of 98 C for 10 s, 65 C for 30 s, and 72 C for 30 s; and 72 C for 2 min. 561_01_18_DINS was generated by cloning a synthesized (Eurofins Genomics) heavy-chain variable region DNA fragment of 1-18 lacking the CDRH1 insertion ( 28 PYTDDD 33 ). PCR products or synthesized DNA fragments were cloned into human antibody expression vectors (IgG1, kappa, or lambda chain) by SLIC assembly as previously described (von Boehmer et al., 2016) . Antibodies were produced in 293-6E cells (National Research Council Canada) by transfection using 25 kDa branched polyethylenimine (PEI) (Sigma-Aldrich). Cells were maintained at 37 C and 6% CO2 in FreeStyle 293 Expression Medium (Thermo Fisher) and 0.2% penicillin/streptomycin (Thermo Fisher). 5-7 days after transfection, culture supernatants were harvested, filtered, and incubated with Protein G Sepharose (GE Life Sciences) overnight at 4 C. Antibodies were eluted from chromatography columns using 0.1 M glycine (pH = 3.0) and buffered in 1 M Tris (pH = 8.0). Subsequent buffer exchange to PBS and antibody concentration was performed using Amicon 30 kDa spin membranes (Millipore). Antibodies were filter-sterilized using Ultrafree-CL or Ultrafree-MC 0.22 mm membranes (Millipore) and stored at 4 C.
Pseudovirus Production
Pseudoviruses for the 12-strain global screening panel and f61 finger printing panel were produced in HEK293T cells by co-transfection with pSG3DEnv plasmid as described previously Hraber et al., 2017; Sarzotti-Kelsoe et al., 2014; Seaman et al., 2010) . Single genome sequencing (SGS)-derived pseudoviruses were generated by co-transfection of SGS-derived CMV promoter-Env products and pSG3DEnv as previously described (Kirchherr et al., 2007) . For sequences obtained from mice, env/rev cassettes were amplified from the first-round SGS PCR product using primers env1Atopo 5 0 -CACCGGCTTAGGCATCTCC TATGGCAGGAAGAA and envB3in 5 0 -CACCTTAGGCATCTCCTATGGCAGGAAGAAG. Pseudoviruses were only produced from sequences containing no ambiguities. For patient-derived sequences, env/rev cassettes were amplified from the first-round SGS product using primers env1Atopo and Rev19 5 0 -ACTTTTTGACCACTTGCCACCCAT. CMV promoter and env/rev overlap PCR was performed using primers CMVenv 5 0 -AGTAATCAATTACGGGGTCATTAGTTCAT and Rev19. Mouse-derived sequences were amplified using the Platinum Taq High Fidelity Polymerase (Thermo Fisher), patient-derived sequences using the Phusion Hot Start Flex Polymerase (New England Biolabs).
Neutralization Assays
Neutralization assays were performed as previously described (Sarzotti-Kelsoe et al., 2014) . In brief, pseudoviruses and dilution series of antibodies or purified IgG were mixed and co-incubated at 37 C for 1 h, followed by the addition of TZM-bl cells at a final concentration of 10 4 cells per well on a 96-well plate in 250 ml medium supplemented with DEAE-dextran at a final concentration of 10 mg/ml. Following a 2-day incubation at 37 C and 5% CO 2 , 150 ml of culture supernatant was removed and 100 ml luciferase assay reagent was added. After a 2 min incubation, 150 ml of lysate was transferred to a black microtiter assay plate and luminescence was determined using a luminometer. After subtracting background relative luminescence units (RLUs) of non-infected TZM-bl cells, 50% and 80% inhibitory concentrations (IC 50 s and IC 80 s) were determined as the antibody/IgG concentrations resulting in a 50%/80% RLU reduction compared to untreated virus control wells. Murine leukemia virus (MuLV)-pseudotyped virus was used to determine unspecific activity. Initial screening of isolated antibody clonal members was performed using a single dilution series per antibody. Antibodies or purified serum IgG in all further neutralization assays were tested in duplicates. For screening assays, assays against culture-derived viruses, assays of pseudovirus mutant variants, and assays of IDC561-derived pseudoviruses, bioluminescence was determined after adding a luciferin/lysis-buffer (10 mM MgCl2, 0.3 mM ATP, 0.5 mM Coenzyme A, 17 mM IGEPAL (all Sigma-Aldrich), and 1 mM D-Luciferin (GoldBio) in Tris-HCL). For assays against the 119-pseudovirus panel, the 100-pseudovirus clade C panel, and the f61 panel, bioluminescence was determined after adding Bright-Glo reagent (Promega).
Neutralization Fingerprinting Panel-Based Antibody Epitope Prediction
Computational epitope prediction of serum IgG neutralizing activity was conducted as previously described . In brief, neutralizing serum IgG activity was determined against the 20 pseudoviruses included in the f61 fingerprinting panel by a TZM-bl cell neutralization assay as described above. The determined IgG neutralization fingerprint is compared to the fingerprint of 10 bNAbs picked as reference for their specific epitope, and the prevalence of these reference antibody epitope specificities is computationally predicted and assigned a delineation score between 0 (low) and 1 (high).
HIV-1 Envelope Protein Production and Purification YU2 gp120 , YU2 gp140 (foldon trimer), and BaL gp140 (foldon trimer) (Pietzsch et al., 2010) were produced in 293-6E cells after transfection with polyethylenimine. Proteins were purified from culture supernatants using Ni-NTA Agarose beads (Macherey-Nagel) according to the manufacturer's instructions and stored at À80 C until further use after buffer exchange to PBS. eOD-GT8 was produced as previously described (Dosenovic et al., 2019) . 93THO527 (Anderson et al., 2000) was produced in 293-6E cells in the presence of kifunensine at a concentration of 1 mg/l.
HIV-1 Env ELISAs
High-binding ELISA plates (Corning) were coated with HIV-1 Env antigens at 2 mg/ml in PBS overnight at 4 C. Wells were blocked with 3% BSA (Sigma Aldrich) in PBS for 60 min at 37 C. HIV-1 antibodies were diluted in PBS and incubated for 60 min at RT, followed by horseradish peroxidase (HRP)-conjugated anti-human IgG (Jackson ImmunoResearch) diluted 1:1,000 in 3% BSA in PBS for 60 min at room temperature (RT). Absorbance was determined on a microplate reader (Tecan) after addition of ABTS solution (Thermo Fisher). Plates were washed with 0.05% Tween 20 (Carl Roth) in PBS between each step. CNE8  CNE55  246F3  X2278  Tro11  CH119  BJOX2000  25710  CE1176  CE0217  X1632  WT  E102K  N160K  N160T  T162I  T162N  N276D  T278K  T278A  T278I  N279K  N279H  N280Y  A281T  T278A+281T  N295S  N301D  N332K  N332S  N332Y  S334D  S334N  G366E  N365L  I371M  E429K  N448Q  G458D  G459D (legend continued on next page) (B) Comparison of Env-interactions of 1-18, the CD4bs bNAbs N6 and 8ANC131, and CD4 at four sites: D368 gp120 , Loop D, the 'Phe43 pocket', and the V5 loop. Heavy chains are shown in darker colors than light chains. PDB codes are indicated on the left. (C) Comparison of Env-interactions of bNAbs with Asp-rich insertions in CDRH1 or FWRH3 contacting the adjacent gp120 protomer. Each SOSIP.664 trimer is shown as semi-transparent surface with the primary gp120 protomer in white and the adjacent gp120 in gray. V H V L regions are shown in teal with insertions in red. PDB code, insertion location, and insertion sequence are listed. (D) Differences between Fabs of 1-18 and 1-55. One 1-18 V H V L (dark green surface) is shown bound to one gp120 (gray cartoon). Locations of residues varying between 1-18 and 1-55 are highlighted in magenta. Glycans at positions N197 gp120 and N276 gp120 are shown as red sticks. 1-55 Fabs were based on earlier sequence variants and contained primer-induced mutations at the start and end of the V genes (for a total of 2 aa [V H] and 4 aa [V K] mutations). 4 g/ml 3 g/ml 4 g/ml 4 g/ml 11 g/ml 8 g/ml 11 g/ml 11 g/ml 11 g/ml 4 g/ml 8 g/ml 4 g/ml 8 g/ml 119, 207, 304, 318 197, 209, 279, 326, 369 119, 120, 182, 197, 204, 206, 207, 209, 274, 279, 304, 308, 318, 369, 471 Sites of significant escape (legend on next page) Figure S5 . Mutational Antigenic Profiling: Fractions Surviving, Correlation between Replicates, and Determination of Sites of Significant Escape, Related to Figure 5 (legend continued on next page)
